BSEM Stock — Biostem Technologies Inc

Biostem Technologies Inc (BSEM)

Updated October 16, 2026.

BSEM is a Stock. Its deepest 1-year drawdown was 75.1%.

BioStem Technologies develops, manufactures, and commercializes placental-derived allografts for advanced wound care and regenerative therapies, with product offerings including tissue matrices for wound covering, soft tissue repair, and ocular surface applications. The company's distribution profile and current dividend policy are not established. This security may appeal to investors seeking exposure to regenerative medicine and advanced wound care technology.

BSEM performance

Returns are updating. BSEM's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 75.1%.

BSEM key facts

Asset type

Stock

Asset class

Equity

Inception date

03/24/1998

Distribution frequency

None

Last close

$2.09 (as of 2026-10-16)

Market cap

$39,024,741

Average volume

33305.0

Beta

0.501

Payout ratio

0.0%

P/E ratio

2.38

Forward P/E

17.4216

EPS

$0.88

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BSEM risks and drawbacks

The deepest 1-year drawdown on record here is 75.1%.

Who may consider BSEM — and who may not

It is a weaker fit for investors who need monthly cash flow (BSEM does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on BSEM

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions